Explaining positive results from a Phase 3 pancreatic cancer study of an experimental drug
Dr. Paul Oberstein, a pancreatic cancer expert and member of the Academic GI Cancer Consortium (AGICC), discusses new data showing positive results from a Phase 3 pancreatic cancer study of an experimental drug by Revolution Medicines.
How are nanoparticles enhancing radiation therapy in lung cancer?
In an interview, Jared Weiss, M.D., from the UNC Lineberger Cancer Center and Criterium’s Academic Thoracic Oncology Medical Investigators Consortium (ATOMIC) explains the mechanism of action of a novel radioenhancer.
Learn more about nanoparticles and radiation therapy in lung cancer
Dr. Pusztai Discusses the Launch of the DARE Study in ER+/HER2– High-Risk Breast Cancer
Lajos Pusztai, M.D., D.Phil., from the Yale Cancer Center and Criterium’s Academic Breast Cancer Consortium (ABRCC) discusses the importance of the DARE study and its potential impact on clinical practice.
Learn about the DARE Study in ER+/HER2 breast cancer
Project grant awarded by the National Cancer Institute to research connections between APOBEC mutagenesis and cancer
The University of Texas at San Antonio was awarded a $10 million project grant from the National Cancer Institute to research connections between APOBEC mutagenesis and cancer. Douglas Yee, MD, from Criterium’s Academic Breast Cancer Consortium (ABRCC) and the University of Minnesota will help oversee this promising collaboration that could illuminate the process of mutation that drives and accelerates cancer.
Learn about this new project funded by the National Cancer Institute